

William P. Deni, Jr.  
Charles H. Chevalier  
J. Brugh Lower  
**GIBBONS P.C.**  
One Gateway Center  
Newark, New Jersey 07102  
Tel: (973) 596-4500  
Fax: (973) 596-0545

*Attorneys for Plaintiffs*

**UNITED STATES DISTRICT COURT  
DISTRICT OF NEW JERSEY**

VALEANT PHARMACEUTICALS  
NORTH AMERICA LLC; VALEANT  
PHARMACEUTICALS IRELAND LTD.;  
DOW PHARMACEUTICAL SCIENCES, INC.;  
and KAKEN PHARMACEUTICAL CO., LTD.,

Plaintiffs,

v.

AUROBINDO PHARMA USA INC. and  
AUROBINDO PHARMA LTD.,

Defendants.

Civil Action No. 18-17733

*Document Electronically Filed*

**COMPLAINT FOR PATENT INFRINGEMENT**

Plaintiffs Valeant Pharmaceuticals North America LLC (“Valeant”), Valeant Pharmaceuticals Ireland Ltd. (“Valeant Ireland”), Dow Pharmaceutical Sciences, Inc. (“Dow”), and Kaken Pharmaceutical Co., Ltd. (“Kaken”) (collectively, “Plaintiffs”) by way of this Complaint against Aurobindo Pharma USA Inc. (“Aurobindo USA”) and Aurobindo Pharma Ltd. (“Aurobindo India”) (collectively, “Aurobindo” or “Defendants”) allege as follows:

**THE PARTIES**

1. Plaintiff Valeant is a limited liability company organized and existing under the

laws of Delaware having its principal place of business at 400 Somerset Corporate Boulevard, Bridgewater, New Jersey 08807.

2. Plaintiff Valeant Ireland is a company existing under the laws of Ireland having an office at 3013 Lake Drive, Citywest Business Campus, Dublin 24, Ireland.

3. Plaintiff Dow is a corporation organized and existing under the laws of Delaware having its principal place of business at 1330 Redwood Way, Petaluma, California 94954.

4. Plaintiff Kaken is a corporation organized and existing under the laws of Japan having its principal place of business at 20th Floor, Bunkyo Green Court, 28-8, Honkomagome 2-chome, Bunkyo-ku, Tokyo 113-8650, Japan.

5. Upon information and belief, Aurobindo USA is a Delaware corporation having a principal place of business at 279 Princeton-Hightstown Rd, East Windsor, NJ 08520-1401.

6. Upon information and belief, Aurobindo India is an Indian corporation having a principal place of business at Water Mark Building, Plot No. 11, Survey no.9, Kondapur, Hitech City, Hyderabad - 500 084, Telangana, India.

7. Upon information and belief, Aurobindo USA is the United States corporate headquarters of Aurobindo India.

### **NATURE OF THE ACTION**

8. This is an action for infringement of United States Patent No. 10,105,444 (“the ‘444 Patent”) arising under the United States patent laws, Title 35, United States Code, § 100 et seq., including 35 U.S.C. §§ 271 and 281. This action relates to Aurobindo’s filing of an Abbreviated New Drug Application (“ANDA”) under section 505(j) of the Federal Food, Drug, and Cosmetic Act (“the Act”), 21 U.S.C. § 355(j), seeking U.S. Food and Drug Administration (“FDA”) approval to market its generic efinaconazole topical solution, 10% (“Aurobindo’s

generic efinaconazole topical solution”).<sup>1</sup>

### **JURISDICTION AND VENUE**

9. This Court has subject matter jurisdiction under 28 U.S.C. §§ 1331, 1338(a), and 2201-02.

10. Upon information and belief, this Court has jurisdiction over Aurobindo USA. Upon information and belief, Aurobindo USA is in the business of, *inter alia*, developing, manufacturing, marketing, importing, and selling pharmaceutical products, including generic drug products. Upon information and belief, Aurobindo USA directly, or indirectly, develops, manufactures, markets, and sells generic drug products throughout the United States and in this judicial district, and this judicial district is a likely destination for Aurobindo USA’s generic efinaconazole topical solution. Upon information and belief, Aurobindo USA is a corporation having principal place of business at 279 Princeton-Hightstown Rd, East Windsor, NJ 08520-1401. Upon information and belief, Aurobindo USA operates a distribution center at 6 Wheeling Road, Dayton, NJ 08810. Upon information and belief, Aurobindo USA purposefully has conducted and continues to conduct business in this judicial district. Upon information and belief, Aurobindo USA has previously submitted to the jurisdiction of this Court and has further previously availed itself of this Court by asserting counterclaims in other civil actions initiated in this jurisdiction.

11. Aurobindo USA has taken the costly, significant step of applying to the FDA for approval to engage in future activities—including the marketing of its generic drugs—that will

---

<sup>1</sup> Plaintiffs previously brought an action for infringement of United States Patent Nos. 7,214,506 (“the ’506 patent”), 8,039,494 (“the ’494 patent”), 8,486,978 (“the ’978 patent”), 9,302,009 (“the ’009 patent”), 9,566,272 (“the ’272 patent”), 9,662,394 (“the ’394 patent”), 9,861,698 (“the ’698 patent”), and 9,877,955 (“the ’955 patent”). That action is currently pending in this Court as Case No. 3:18-cv-13693 (PGS) (LHG), and Plaintiffs hereby incorporate by reference their Complaint against Aurobindo (ECF No. 1) in that action.

be purposefully directed at, upon information and belief, the State of New Jersey and elsewhere. Aurobindo USA's ANDA filings constitute formal acts that reliably indicate plans to engage in marketing of the proposed generic drugs. Upon information and belief, Aurobindo USA intends to direct sales of its drugs into New Jersey, among other places, once it has the requested FDA approval to market them. Upon information and belief, Aurobindo USA will engage in marketing of its proposed ANDA products in New Jersey upon approval of its ANDA.

12. Upon information and belief, this court has jurisdiction over Aurobindo India. Upon information and belief, Aurobindo India is in the business of, *inter alia*, developing, manufacturing, marketing, importing, and selling pharmaceutical products, including generic drug products. Upon information and belief, Aurobindo India directly, or indirectly, develops, manufactures, markets, and sells generic drug products throughout the United States and in this judicial district, and this judicial district is a likely destination for Aurobindo's generic efinaconazole topical solution. Upon information and belief, Aurobindo India purposefully has conducted and continues to conduct business in this judicial district.

13. Aurobindo USA and Aurobindo India know or should know that Jublia<sup>®</sup> is manufactured for Valeant Pharmaceuticals North America LLC in Bridgewater, NJ 08807 USA at least because that information is included in the label and prescribing information for Jublia<sup>®</sup>.

14. Upon information and belief, venue is proper in this judicial district under 28 U.S.C. §§ 1391(c) and (d), and § 1400(b).

15. Venue is proper against Aurobindo USA because it operates a principal place of business in this judicial district.

16. Venue is proper against Aurobindo India, a foreign corporation, in any judicial district that has personal jurisdiction, including this judicial district.

### **THE PATENT IN SUIT**

17. The United States Patent and Trademark Office (“PTO”) issued the ’444 patent on October 23, 2018. The ’444 patent claims, generally speaking, *inter alia*, pharmaceutical formulations including ethanol, cyclomethicone, diisopropyl adipate, C12-15 alkyl lactate and antioxidant. Plaintiffs hold all substantial rights in the ’444 patent and have the right to sue for infringement thereof. The ’444 patent is valid and enforceable. A copy of the ’444 patent is attached hereto as Exhibit A.

18. Dow is the holder of New Drug Application (“NDA”) No. 203567 for Jublia®, which the FDA approved on June 6, 2014. In conjunction with NDA No. 203567, the ’444 patent are listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations (“the Orange Book”).

19. Efinaconazole topical solution, 10% is sold in the United States under the trademark Jublia®.

### **AUROBINDO’S INFRINGING ANDA SUBMISSION**

20. Upon information and belief, Aurobindo USA filed or caused to be filed with the FDA ANDA No. 212066, under Section 505(j) of the Act and 21 U.S.C. § 355(j).

21. Upon information and belief, Aurobindo USA’s ANDA No. 212066 seeks FDA approval to sell in the United States Aurobindo’s generic efinaconazole topical solution, intended to be a generic version of Jublia®.

22. Dow received a letter dated November 13, 2018 from Aurobindo USA purporting to be a Notice of Certification for ANDA No. 212066 (“Aurobindo’s notice letter”) under Section 505(j)(2)(B)(ii) of the Act, 21 U.S.C. § 355(j)(2)(B)(ii), and 21 C.F.R. § 314.95(c) that included a certification pursuant to 21 U.S.C. § 355(j)(2)(A)(vii)(IV).

23. Aurobindo's notice letter alleges that Aurobindo USA has submitted to the FDA ANDA No. 212066 seeking FDA approval to sell Aurobindo's generic efinaconazole topical solution, intended to be a generic version of Jublia®.

24. Upon information and belief, ANDA No. 212066 seeks approval of Aurobindo's generic efinaconazole topical solution that is the same, or substantially the same, as Jublia®.

### **COUNT I AGAINST AUROBINDO**

#### **Infringement of the '444 Patent under § 271(e)(2)**

25. Paragraphs 1-24 are incorporated herein as set forth above.

26. Under 35 U.S.C. § 271(e)(2), Aurobindo has infringed at least one claim of the '444 patent by submitting, or causing to be submitted to the FDA, ANDA No. 212066 seeking approval for the commercial marketing of Aurobindo's generic efinaconazole topical solution before the expiration date of the '444 patent.

27. Upon information and belief, Aurobindo's generic efinaconazole topical solution will, if approved and marketed, infringe, either literally or under the doctrine of equivalents, at least one claim of the '444 patent.

28. Upon information and belief, Aurobindo will, through the manufacture, use, import, offer for sale, and/or sale of Aurobindo's generic efinaconazole topical solution, directly infringe, contributorily infringe, and/or induce infringement of at least one claim of the '444 patent.

29. If Aurobindo's marketing and sale of its generic efinaconazole topical solution prior to the expiration of the '444 patent is not enjoined, Plaintiffs will suffer substantial and irreparable harm for which there is no adequate remedy at law.

**COUNT II AGAINST AUROBINDO**

**Declaratory Judgment of Infringement of the '444 Patent**

30. Paragraphs 1-29 are incorporated herein as set forth above.

31. These claims arise under the Declaratory Judgment Act, 28 U.S.C. §§ 2201 and 2202.

32. There is an actual case or controversy such that the Court may entertain Plaintiffs' request for declaratory relief consistent with Article III of the United States Constitution, and this actual case or controversy requires a declaration of rights by this Court.

33. Aurobindo has made, and will continue to make, substantial preparation in the United States to manufacture, use, offer to sell, sell, and/or import Aurobindo's generic efinaconazole topical solution before the expiration date of the '444 patent, including Aurobindo's filing of ANDA No. 212066.

34. Upon information and belief, any commercial manufacture, use, offer for sale, sale, and/or importation of Aurobindo's generic efinaconazole topical solution will directly infringe, contributorily infringe, and/or induce infringement of at least one claim of the '444 patent.

35. Plaintiffs are entitled to a declaratory judgment that future commercial manufacture, use, offer for sale, sale, and/or importation of Aurobindo's generic efinaconazole topical solution will constitute infringement of at least one claim of the '444 patent.

**PRAYER FOR RELIEF**

**WHEREFORE**, Plaintiffs respectfully request that the Court enter judgment in their favor and against Aurobindo on the patent infringement claims set forth above and respectfully request that this Court:

1. enter judgment that, under 35 U.S.C. § 271(e)(2), Aurobindo has infringed at least one claim of the '444 patent by submitting or causing to be submitted ANDA No. 212066 to the FDA to obtain approval for the commercial manufacture, use, import, offer for sale, and/or sale in the United States of Aurobindo's generic efinaconazole topical solution before the expiration of the '444 patent;

2. order that that the effective date of any approval by the FDA of Aurobindo's generic efinaconazole topical solution be a date that is not earlier than the expiration of the '444 patent, or such later date as the Court may determine;

3. enjoin Aurobindo from the commercial manufacture, use, import, offer for sale, and/or sale of Aurobindo's generic efinaconazole topical solution until expiration of the '444 patent, or such later date as the Court may determine;

4. enjoin Aurobindo and all persons acting in concert with Aurobindo from seeking, obtaining, or maintaining approval of Aurobindo's ANDA No. 212066 until expiration of the '444 patent;

5. declare this to be an exceptional case under 35 U.S.C. §§ 285 and 271(e)(4) and award Plaintiffs costs, expenses, and disbursements in this action, including reasonable attorney's fees;

6. award Plaintiffs such further and additional relief as this Court deems just and proper.



Dated: December 28, 2018  
Newark, New Jersey

Respectfully submitted,

s/ William P. Deni, Jr.

William P. Deni, Jr.  
Charles H. Chevalier  
J. Brugh Lower

**GIBBONS P.C.**

One Gateway Center  
Newark, New Jersey 07102  
Tel: (973) 596-4500  
Fax: (973) 596-0545  
wdeni@gibbonslaw.com  
cchevalier@gibbonslaw.com  
jlower@gibbonslaw.com

*Attorneys for Plaintiffs*

**Of Counsel:**

Thomas P. Steindler (*pro hac vice* to be submitted)  
Nicole M. Jantzi (*pro hac vice* to be submitted)  
Paul M. Schoenhard (*pro hac vice* to be submitted)  
Ian B. Brooks (*pro hac vice* to be submitted)

**MCDERMOTT WILL & EMERY LLP**

The McDermott Building  
500 North Capitol Street, NW  
Washington, DC 20001-1531  
(202) 756-8000

*Attorneys for Plaintiffs*  
*Valeant Pharmaceuticals North America LLC,*  
*Valeant Pharmaceuticals Ireland Ltd., and*  
*Dow Pharmaceutical Sciences, Inc.*

John D. Livingstone (*pro hac vice* to be submitted)

**FINNEGAN, HENDERSON,  
FARABOW, GARRETT & DUNNER, LLP**

271 17th Street, NW  
Suite 1400  
Atlanta, GA 30363-6209  
(404) 653-6400

Naoki Yoshida (*pro hac vice* to be submitted)

**FINNEGAN, HENDERSON,  
FARABOW, GARRETT & DUNNER, LLP**

33rd Floor, Shiroiyama Trust Tower  
3-1, Toranomom 4-chome, Minato-ku

Tokyo, 105-6033 Japan  
+81-3-3431-6943

*Attorneys for Plaintiff*  
*Kaken Pharmaceutical Co., Ltd.*

**CERTIFICATION OF NON-ARBITRABILITY**  
**PURSUANT TO LOCAL CIVIL RULE 201.1(d)**

Pursuant to Local Civil Rule 201.1(d), the undersigned counsel hereby certifies that this action seeks declaratory and injunctive relief and, therefore, is not subject to mandatory arbitration.

I hereby certify under penalty of perjury that the foregoing is true and correct.

Dated: December 28, 2018  
Newark, New Jersey

Respectfully submitted,

s/ William P. Deni, Jr.

William P. Deni, Jr.

**GIBBONS P.C.**

One Gateway Center

Newark, New Jersey 07102

Tel: (973) 596-4500

Fax: (973) 596-0545

wdeni@gibbonslaw.com

*Attorneys for Plaintiffs*